AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies

Jefferies highlights that Johnson & Johnson’s Spravato posted Q4 2025 TRD sales of $503m, up 10% sequentially and implying a run-rate above $2bn, keeping J&J on track for $3.0–$3.5bn in annual sales by 2027–28. The firm argues Spravato’s commercial traction validates psychedelics as a viable mental-health revenue stream and identifies AtaiBeckley (ATAI) as a direct beneficiary—citing its intranasal 5‑MeO‑DMT candidate BPL‑003’s fit with Spravato’s 2‑hour clinic paradigm, a potential 2–3 month redosing cadence, Phase II data and a planned Q1 2026 two‑dose induction trial (with a 12‑week dataset due Q4 2026). Jefferies also notes potential upside to COMPASS’s COMP360 and that Atai holds <7% of CMPS, implying both direct and indirect commercial and perception benefits for psychedelic-focused equities.

Analysis

Market structure: Spravato’s >$2bn run-rate (Q4 $503m) validates a clinic-delivered psychedelics commercial model and directly benefits device suppliers (Aptar partners), clinic operators, JNJ, and candidates that mirror Spravato’s 2-hour outpatient paradigm — notably ATAI’s BPL-003 and COMP360 (CMPS). BPL-003’s 2–3 month redosing materially changes revenue cadence vs Spravato (up to 52x/yr) — pricing per administration can be higher but total annual per-patient revenue depends on adoption; expect early share gains for programs that plug into existing Spravato infrastructure (6–24 month window).

Risk assessment: Primary tail risks are regulatory tightening (REMS expansion, CMS non-coverage), acute safety signals in 1–2 pivotal trials, and manufacturing/device supply bottlenecks (Aptar capacity) that could delay commercialization into 2027–2028. Time-sensitive catalysts: ATAI Phase IIa (two-dose) in Q1 2026 and a 12-week dataset in Q4 2026; COMPASS datasets in H1 2026 — negative readouts or payer refusals within these windows could trigger >40% drawdowns.

Trade implications: Tactical allocation: overweight ATAI (idiosyncratic exposure to BPL-003 fit) and modestly increase exposure to CMPS (<7% stake-linked upside) while hedging sector beta. Use calibrated option exposure into Q1 and Q4 2026 readouts (defined-risk call spreads) and prefer 1–3% notional sizing for longs with 20–30% stop-losses; reduce broad pharma defensive longs only if risk-on to small-cap biotech persists.

Contrarian angles: Consensus underestimates payer friction and clinic-capacity limits — Spravato’s scale doesn’t guarantee universal acceptance; BPL-003’s less frequent dosing could paradoxically limit revenue per patient vs Spravato unless pricing captures value. Historical parallel: rapid ketamine clinic growth later constrained by reimbursement and safety oversight; monitor CMS coding decisions and Aptar device orderbook (next 60–90 days) as leading indicators that consensus upside is real vs overcooked.

Key Decisions for Investors

• Establish a 2–3% long position in AtaiBeckley (NASDAQ:ATAI) ahead of the Q1 2026 Phase IIa two-dose readout; set an initial stop-loss at -25% and plan to trim to 1% exposure on a pre-readout run-up >30%.
• Allocate 0.5–1.0% of portfolio to a defined-risk ATAI call spread expiring Q4 2026 (captures the 12-week dataset) to asymmetrically capture upside while limiting premium loss; target >2x payoff on positive data and cap max loss at premium paid.
• Add a 1% long position in COMPASS Pathways (NASDAQ:CMPS) ahead of H1 2026 datasets, but hedge 50% of this position by shorting equivalent beta exposure to the iShares Biotechnology ETF (IBB) to isolate psychedelic-specific risk.
• Reduce broad defensive pharma exposure by 1–2% and reallocate into clinic/service names and Aptar/device suppliers if platform signals arrive (Aptar order disclosures or CMS coding) within the next 60–90 days; if CMS signals non-coverage or REMS expansion occur, liquidate psychedelic exposure >50% immediately.